Literature DB >> 2644979

Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases.

J Ben-Ezra1, J S Burke, W G Swartz, M D Brownell, R K Brynes, L R Hill, B N Nathwani, M M Oken, B C Wolf, R Woodruff.   

Abstract

We analyzed specimens from 268 patients with small lymphocytic lymphoma (SL) to identify prognostic factors significant for survival. These patients were staged and treated according to the protocols of the Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, Southeastern Cancer Study Group, and the Southwest Oncology Group. Univariate analysis showed that a large-cell grade greater than I, WBC greater than 10,000/microL, hemoglobin (Hgb) less than 11 g/dL, age greater than or equal to 55 years, and failure to respond to treatment were all poor prognostic factors. Multivariate analysis showed that large-cell grade, age, degree of capsular invasion, and symptom type were independently associated with survival. Separate analyses of cases with and without leukocytosis indicated differences in survival. In patients without leukocytosis, age, presence or absence of anemia, and treatment response were significant prognostic variables; in patients with leukocytosis, large-cell grade, presence or absence of anemia, symptom type, and treatment response were significantly related to survival. Multivariate analysis showed that age was the only significant independent prognostic variable in patients without leukocytosis; in patients with leukocytosis, symptom type, large-cell grade, and bone marrow involvement were independently associated with survival. We conclude that several parameters, both clinical and pathologic, should be assessed at the initial diagnosis of SL to predict prognosis better.

Entities:  

Mesh:

Year:  1989        PMID: 2644979

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.

Authors:  Eva Giné; Antoni Martinez; Neus Villamor; Armando López-Guillermo; Mireia Camos; Daniel Martinez; Jordi Esteve; Xavier Calvo; Ana Muntañola; Pau Abrisqueta; Maria Rozman; Ciril Rozman; Francesc Bosch; Elias Campo; Emili Montserrat
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 2.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

3.  Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis.

Authors:  Sarah E Gibson; Steven H Swerdlow; Judith A Ferry; Urvashi Surti; Paola Dal Cin; Nancy Lee Harris; Robert P Hasserjian
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

4.  Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia.

Authors:  Maura Rossi; Fabio Fuligni; Maria Ciccone; Claudio Agostinelli; Simona Righi; Marco Luciani; Maria Antonella Laginestra; Gian Matteo Rigolin; Maria Rosaria Sapienza; Anna Gazzola; Claudia Mannu; Antonio Cuneo; Stefano Pileri; Pier Paolo Piccaluga
Journal:  Biomed Res Int       Date:  2013-12-12       Impact factor: 3.411

5.  Small Lymphocytic Lymphoma Presenting as a Breast Lump: A Rare Presentation of Non-Hodgkin's Lymphoma.

Authors:  Nazia Khan; Hamid Shaaban; Gunwant Guron
Journal:  Cureus       Date:  2021-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.